1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Aplagon Oy: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg, - Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia | Phase 2 | Recruiting | Aplagon Oy | 42 | 2026-01-29 | 2026-04-09 |
Chronic Limb-Threatening Ischemia (1) · Peripheral Arterial Occlusive Disease 1 (1)
Heparin (1) · Sodium Chloride (1)
Finland (1)
2025 (1)